Radioligands are safe and effective cancer treatments that have been used for many years to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumours, thyroid cancer and, most recently, prostate cancer.
Compared to chemotherapy, which can cause extensive damage to healthy cells, radioligands precisely deliver a radioactive payload that kills cancer cells and leaves surrounding healthy cells untouched. The immune system is then mobilized to the site of disease, amplifying the therapeutic effect.
Our objective is to provide the right medicine at the right time for the right patient. By combining radioligands with companion molecular imaging agents and PET/CT, physicians can make informed treatment decisions and select patients that will respond to treatment for the best outcomes.